366 related articles for article (PubMed ID: 3712277)
21. 5-HT receptors mediating external carotid vasoconstriction in vagosympathectomized dogs.
Villalón CM; Centurión D; Sánchez-López A; De Vries P; Saxena P
Zhongguo Yao Li Xue Bao; 1999 Dec; 20(12):1057-67. PubMed ID: 11216445
[TBL] [Abstract][Full Text] [Related]
22. Cisapride and 5-hydroxytryptamine enhance motility in the canine antrum via separate pathways, not involving 5-hydroxytryptamine1,2,3,4 receptors.
de Ridder WJ; Schuurkes JA
J Pharmacol Exp Ther; 1993 Jan; 264(1):79-88. PubMed ID: 8093733
[TBL] [Abstract][Full Text] [Related]
23. LY215840, a high-affinity 5-HT7 receptor ligand, blocks serotonin-induced relaxation in canine coronary artery.
Cushing DJ; Zgombick JM; Nelson DL; Cohen ML
J Pharmacol Exp Ther; 1996 Jun; 277(3):1560-6. PubMed ID: 8667223
[TBL] [Abstract][Full Text] [Related]
24. Multiple serotonin receptors and their physiological significance.
Peroutka SJ; Snyder SH
Fed Proc; 1983 Feb; 42(2):213-7. PubMed ID: 6337063
[TBL] [Abstract][Full Text] [Related]
25. LY215840, a potent 5-hydroxytryptamine (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2 receptors and delays occlusion in a rabbit model of thrombosis.
Cohen ML; Robertson DW; Bloomquist WE; Wilson HC
J Pharmacol Exp Ther; 1992 Apr; 261(1):202-8. PubMed ID: 1560366
[TBL] [Abstract][Full Text] [Related]
26. The 5-HT1-like receptors mediating inhibition of sympathetic vasopressor outflow in the pithed rat: operational correlation with the 5-HT1A, 5-HT1B and 5-HT1D subtypes.
Villalón CM; Centurión D; Rabelo G; de Vries P; Saxena PR; Sánchez-López A
Br J Pharmacol; 1998 Jul; 124(5):1001-11. PubMed ID: 9692787
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular effects of serotonin agonists and antagonists.
Saxena PR; Villalón CM
J Cardiovasc Pharmacol; 1990; 15 Suppl 7():S17-34. PubMed ID: 1702484
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological characterization of the 5-HT receptors mediating contraction and relaxation of canine isolated proximal stomach smooth muscle.
Janssen P; Prins NH; Meulemans AL; Lefebvre RA
Br J Pharmacol; 2002 May; 136(2):321-9. PubMed ID: 12010782
[TBL] [Abstract][Full Text] [Related]
29. Involvement of specific receptors and calcium mechanisms in serotonergic contractile response of isolated cerebral and peripheral arteries from rats.
Chang JY; Owman C
J Pharmacol Exp Ther; 1987 Aug; 242(2):629-36. PubMed ID: 3612555
[TBL] [Abstract][Full Text] [Related]
30. Characterization of the receptors involved in the 5-HT-induced excitation of canine antral longitudinal muscle.
Prins NH; Akkermans LM; Lefebvre RA; Schuurkes JA
Br J Pharmacol; 2001 Nov; 134(6):1351-9. PubMed ID: 11704657
[TBL] [Abstract][Full Text] [Related]
31. The 5-hydroxytryptamine2B receptor and 5-HT receptor signal transduction in mesenteric arteries from deoxycorticosterone acetate-salt hypertensive rats.
Watts SW; Baez M; Webb RC
J Pharmacol Exp Ther; 1996 May; 277(2):1103-13. PubMed ID: 8627522
[TBL] [Abstract][Full Text] [Related]
32. Characterization of the contractile 5-hydroxytryptamine receptor in the renal artery of the normotensive rat.
Watts SW; Thompson JM
J Pharmacol Exp Ther; 2004 Apr; 309(1):165-72. PubMed ID: 14724222
[TBL] [Abstract][Full Text] [Related]
33. Discriminative stimulus properties of quipazine: mediation by serotonin2 binding sites.
Friedman RL; Barrett RJ; Sanders-Bush E
J Pharmacol Exp Ther; 1984 Mar; 228(3):628-35. PubMed ID: 6707913
[TBL] [Abstract][Full Text] [Related]
34. Evidence that 5-HT2 receptors predominantly mediate the contraction of the rat basilar artery to 5-hydroxytryptamine.
Deckert V; Angus JA
Eur J Pharmacol; 1992 Oct; 221(1):17-25. PubMed ID: 1459189
[TBL] [Abstract][Full Text] [Related]
35. Vasoconstrictor mechanism of 5-hydroxytryptamine in isolated and perfused canine basilar arteries.
Tsuji T; Chiba S
Arch Int Pharmacodyn Ther; 1987 Mar; 286(1):111-22. PubMed ID: 3592852
[TBL] [Abstract][Full Text] [Related]
36. Preclinical pharmacology of a new serotonergic receptor antagonist, LY281067.
Cohen ML; Fuller RW; Kurz KD; Parli CJ; Mason NR; Meyers DB; Smallwood JK; Toomey RE
J Pharmacol Exp Ther; 1988 Jan; 244(1):106-12. PubMed ID: 3335993
[TBL] [Abstract][Full Text] [Related]
37. Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist.
Rinaldi-Carmona M; Congy C; Santucci V; Simiand J; Gautret B; Neliat G; Labeeuw B; Le Fur G; Soubrie P; Breliere JC
J Pharmacol Exp Ther; 1992 Aug; 262(2):759-68. PubMed ID: 1501121
[TBL] [Abstract][Full Text] [Related]
38. Serotonin-induced contraction of canine basilar artery: mediation by 5-HT1 receptors.
Peroutka SJ; Noguchi M; Tolner DJ; Allen GS
Brain Res; 1983 Jan; 259(2):327-30. PubMed ID: 6824943
[TBL] [Abstract][Full Text] [Related]
39. Variable participation of 5-HT1-like receptors and 5-HT2 receptors in serotonin-induced contraction of human isolated coronary arteries. 5-HT1-like receptors resemble cloned 5-HT1D beta receptors.
Kaumann AJ; Frenken M; Posival H; Brown AM
Circulation; 1994 Sep; 90(3):1141-53. PubMed ID: 8087924
[TBL] [Abstract][Full Text] [Related]
40. 5-Hydroxytryptamine (5-HT) and SK&F 103829 contract canine lower esophageal sphincter smooth muscle by stimulating 5-HT2 receptors.
Barnette MS; Grous M; Manning CD; Price WJ; Nelson AH; Bondinell WE; Barone FC; Ormsbee HS
Receptor; 1992; 2(3):155-67. PubMed ID: 1472950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
